Company intelligence / Profile preview

Tau-MEDICAL

Ownership: Private
Employees: ~125
Development stage: Preclinical

Overview

Alpha Tau Medical is conducting clinical trials of its proprietary intratumoral alpha-radiation therapy, Alpha DaRT, for a range of solid tumors. The technology has shown promise in delivering highly potent and conformal radiation to tumors while sparing healthy tissue. Trials are ongoing in skin, oral cavity, prostate, pancreatic, and breast cancers; additional studies are planned or underway for other solid tumor types[1][2].

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalDevice (intratumoral radiation delivery)
Industry: Biotech

Drug pipeline

2 assets

Pivot Bridge

Pre-clinical

Indications: Tricuspid valve regurgitation

1 more asset in the full pipeline.

Request access →

Partnerships

Not explicitly listed; works with leading academic centers and researchers on clinical trials[1].

Beyond the preview

Go deeper on Tau-MEDICAL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tau-MEDICAL.

Explore the full profile